Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain.

Thrombolysis with tissue-type plasminogen activator (t-PA) is the only treatment approved for acute ischemic stroke. Although t-PA is an efficient clot lysis enzyme, it also causes damage to the neurovascular unit, including hemorrhagic transformations and neurotoxicity.

• Publication date: Mar 2013
• Journal: Journal of thrombosis and haemostasis : JTH
• Publication date: Parcq J, Bertrand T, Baron AF, Hommet Y, Anglès-Cano E, Vivien D
• ISSN: 1538-7836